GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$41.18 USD
+0.86 (2.13%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.18 USD
+0.86 (2.13%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
Zacks News
AstraZeneca's Lynparza Gets China Nod in First-Line Setting
by Zacks Equity Research
AstraZeneca's (AZN) Lynparza receives approval in China for first-line maintenance treatment of advanced ovarian cancer with BRCA-mutation.
Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.
Are You Looking for a Top Momentum Pick? Why GlaxoSmithKline (GSK) is a Great Choice
by Zacks Equity Research
Does GlaxoSmithKline (GSK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD
by Zacks Equity Research
The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.
Is GlaxoSmithKline (GSK) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bristol-Myers' Reblozyl to be Reviewed by FDA Committee
by Zacks Equity Research
Bristol-Myers (BMY) and Acceleron Pharma Inc.'s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDA's Oncologic Drugs Advisory Committee.
Epizyme Announces FDA Committee Review of Tazemetostat NDA
by Zacks Equity Research
Epizyme (EPZM) announces that the FDA committee will review its NDA for lead candidate, tazemetostat, on Dec 18.
Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda gets FDA's priority review status to treat certain patients with high-risk, non-muscle invasive bladder cancer.
Large-Cap Pharmaceuticals Industry Prospects Bright for 2020
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.
The Zacks Analyst Blog Highlights: Apple, Comcast, NVIDIA, GlaxoSmithKline and Global Payments
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Comcast, NVIDIA, GlaxoSmithKline and Global Payments
Top Analyst Reports for Apple, Comcast & NVIDIA
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Comcast Corporation (CMCSA) and NVIDIA Corporation (NVDA).
Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies
by Zacks Equity Research
Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.
Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs
by Zacks Equity Research
Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.
Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.
AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status
by Zacks Equity Research
The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.
Should Value Investors Buy GlaxoSmithKline (GSK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates
by Kinjel Shah
Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.
4 Big Drugmakers to Bet on After a Great Earnings Season
by Kinjel Shah
Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.
Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study
by Zacks Equity Research
GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.
Merck's Ebola Vaccine Gets Conditional Approval in Europe
by Zacks Equity Research
European Commission grants approval to Merck's (MRK) Ervebo (V920) for active immunization of individuals 18 years and above to protect against Ebola Virus Disease caused by Zaire Ebola virus.
Novartis' Generics Unit to Buy Aspen's Japanese Operations
by Zacks Equity Research
Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.
Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase
by Zacks Equity Research
Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.
Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales
by Zacks Equity Research
Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.
Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates
by Zacks Equity Research
Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.
Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.